LES Boston Chapter Meeting DATE & TIME
Tuesday, October 23, 2012
5:30 PM – 8:00 PM LOCATION
AstraZeneca R&D Boston
35 Gatehouse Drive
Waltham, MA 02451
(781) 839 – 4000 TITLE
New Models for Deal Making in Pharma/Biotech MODERATOR
Robert Ward, VP New Opportunities, Innovative Medicines Group, AstraZeneca PANELISTS
Karen Gallant, VP of Strategic Partnering & Business Development, AstraZeneca
Paulina Hill, Senior Associate, Polaris Venture Partners
TBD, Biotech industry representative DESCRIPTION
A steady shift has taken place in pharma/biotech deal making from outright product licensing to a company acquisition strategy based upon contingent payments. For example, a 2012 M&A Study by SRS Life Sciences revealed that 83% (n=47) of private-target acquisitions involved earn-outs potentially worth >$7 billion. On the surface, the deals appear more lucrative and the payouts occur in a shorter timeframe (< 4 years after acquisition, Source:SRS data). However, with the advantages of these terms comes an increase in the overall risk due to the structure of the payments and a loss of developmental control. SRS Life Sciences estimates that at launch, only 36% of milestone events have been achieved and only 30% of milestone payments have been paid. In this type of evolving deal making environment, what are the key success factors for both sides to consider? Click here for for online registration and meeting information | 
No comments:
Post a Comment